How does adenosine control neuronal dysfunction and neurodegeneration?
RA Cunha - Journal of neurochemistry, 2016 - Wiley Online Library
The adenosine modulation system mostly operates through inhibitory A1 (A1R) and
facilitatory A2A receptors (A2AR) in the brain. The activity‐dependent release of adenosine …
facilitatory A2A receptors (A2AR) in the brain. The activity‐dependent release of adenosine …
Adenosine and brain function
BB Fredholm, JF Chen, RA Cunha… - Int Rev …, 2005 - books.google.com
A. Cellular and Subcellular Localization B. Pharmacological Tools to Study Adenosine
Receptors C. Signaling Via Adenosine Receptors D. Regulation of Receptor Expression and …
Receptors C. Signaling Via Adenosine Receptors D. Regulation of Receptor Expression and …
Astrocyte molecular signatures in Huntington's disease
Astrocytes are implicated in neurodegenerative disorders and may contribute to striatal
neuron loss or dysfunction in Huntington's disease (HD). Here, we assessed striatal …
neuron loss or dysfunction in Huntington's disease (HD). Here, we assessed striatal …
Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease
MT Armentero, A Pinna, S Ferré, JL Lanciego… - Pharmacology & …, 2011 - Elsevier
Several selective antagonists for adenosine A2A receptors (A2AR) are currently under
evaluation in clinical trials (phases I to III) to treat Parkinson's disease, and they will probably …
evaluation in clinical trials (phases I to III) to treat Parkinson's disease, and they will probably …
Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and “fine tuning” modulation
This review summarizes recent developments that have contributed to understand how
adenosine receptors, particularly A2A receptors, modulate brain injury in various animal …
adenosine receptors, particularly A2A receptors, modulate brain injury in various animal …
Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease
K Xu, E Bastia, M Schwarzschild - Pharmacology & therapeutics, 2005 - Elsevier
In the pursuit of improved treatments for Parkinson's disease (PD), the adenosine A2A
receptor has emerged as an attractive nondopaminergic target. Based on the compelling …
receptor has emerged as an attractive nondopaminergic target. Based on the compelling …
Different synaptic and subsynaptic localization of adenosine A2A receptors in the hippocampus and striatum of the rat
Adenosine A2A receptors are most abundant in the striatum where they control the
striatopallidal pathway thus controlling locomotion. Extra-striatal A2A receptors are …
striatopallidal pathway thus controlling locomotion. Extra-striatal A2A receptors are …
Aspects of the general biology of adenosine A2A signaling
Many of our current hopes of finding better ways to treat Parkinson's disease or to stop its
progression rely on studies of adenosine A2A receptors in the brain. Yet any drug targeting …
progression rely on studies of adenosine A2A receptors in the brain. Yet any drug targeting …
The good, the bad, and the deadly: adenosinergic mechanisms underlying sudden unexpected death in epilepsy
Adenosine is an inhibitory modulator of neuronal excitability. Neuronal activity results in
increased adenosine release, thereby constraining excessive excitation. The exceptionally …
increased adenosine release, thereby constraining excessive excitation. The exceptionally …
CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model
SY Chou, YC Lee, HM Chen, MC Chiang… - Journal of …, 2005 - Wiley Online Library
Huntington's disease (HD) is an autosomal dominant neurodegenerative disease caused by
a CAG trinucleotide expansion in exon 1 of the Huntingtin (Htt) gene. We show herein that in …
a CAG trinucleotide expansion in exon 1 of the Huntingtin (Htt) gene. We show herein that in …